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Abstract
Summary FRAX® calculates the 10-year probability of major osteoporotic fractures (MOF), which are considered to have a
greater clinical impact than other fractures. Our results suggest that, in postmenopausal women with severe osteoporosis, those
treated with teriparatide had a 60% lower risk of FRAX®-defined MOF compared with those treated with risedronate.
Introduction The VERO trial was an active-controlled fracture endpoint clinical trial that enrolled postmenopausal women with
severe osteoporosis. After 24 months, a 52% reduction in the hazard ratio (HR) of clinical fractures was reported in patients
randomized to teriparatide compared with risedronate. We examined fracture results restricted to FRAX®-defined major osteo-
porotic fractures (MOF), which include clinical vertebral, hip, humerus, and forearm fractures.
Methods In total, 1360 postmenopausal women (mean age 72.1 years) were randomized to receive subcutaneous daily
teriparatide (20 μg) or oral weekly risedronate (35 mg). Patient cumulative incidence of ≥ 1 FRAX®-defined MOF and of all
clinical fractures were estimated by Kaplan-Meier analyses, and the comparison between treatments was based on the stratified
log-rank test. Additionally, an extended Cox model was used to estimate HRs at different time points. Incidence fracture rates
were estimated at each 6-month interval.
Results After 24 months, 16 (2.6%) patients in the teriparatide group had ≥ 1 low trauma FRAX®-defined MOF compared with
40 patients (6.4%) in the risedronate group (HR 0.40; 95% CI 0.23–0.68; p = 0.001). Clinical vertebral and radius fractures were
the most frequent FRAX®-defined MOF sites. The largest difference in incidence rates of both FRAX®-defined MOF and all
clinical fractures between treatments occurred during the 6- to 12-month period. There was a statistically significant reduction in
fractures between groups as early as 7 months for both categories of clinical fractures analyzed.
Conclusion In postmenopausal women with severe osteoporosis, treatment with teriparatide was more efficacious than
risedronate, with a 60% lower risk of FRAX®-definedMOF during the 24-month treatment period. Fracture risk was statistically
significantly reduced at 7 months of treatment.
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Introduction
Osteoporotic fractures are associated with substantial social,
economic, and healthcare burden. The VERtebral fracture
treatment comparison in Osteoporotic women (VERO) trial
was the first active-controlled, fracture endpoint study in post-
menopausal women with low bone mass and prevalent verte-
bral fractures. VERO compared the effectiveness of the bone-
forming drug teriparatide with that of the antiresorptive
risedronate, with fractures as the primary outcome [1].
Previously, we reported a 52% reduction in the risk of clinical
fractures (a composite of clinical vertebral and non-vertebral
fragility fractures; p < 0.001), a 42% reduction in the risk of
major, fragility non-vertebral fractures (p = 0.06), and a 71%
reduction in the risk of clinical vertebral fractures in patients
randomized to teriparatide compared with risedronate after 24
months of treatment (p = 0.002) [1].
The development of the fracture risk assessment tool or
FRAX® algorithm has led to an improvement in identifying
patients at risk of fracture and provides an opportunity to
identify those most likely to benefit from osteoporosis treat-
ment using easily obtained clinical risk factors for fracture [2].
FRAX® computes the 10-year probability of hip fracture or of
major osteoporotic fractures (MOF), which includes clinical
spine, hip, forearm, and proximal humerus fractures [2]. These
types of fractures are considered to be more related to osteo-
porosis, have greater clinical impact, and are associated with
higher health-related costs than fractures at other sites [2].
Consequently, FRAX®-defined MOF have become an in-
creasingly reported efficacy endpoint in osteoporosis trials
and pharmacoeconomic evaluations [2–5].
In the pre-specified statistical analysis plan of the VERO
trial [1], the list of non-vertebral fractures was defined accord-
ing to the European Guidelines for the Evaluation of Drugs for
the Treatment of Osteoporosis [6]. Here, we present the results
of a post hoc analysis of the fracture results from the VERO
trial, restricted to the MOF included in the FRAX® model.
Moreover, given the importance of early antifracture efficacy
of osteoporosis drugs for patients with severe osteoporosis at
high imminent fracture risk, we also analyzed the time pattern
of the FRAX®-defined MOF antifracture efficacy, and how it
compares with the predefined list of all clinical fractures.
Methods
Study design and participants
The VERO study design has previously been described in
detail [1]. In summary, VERO was an international, multicen-
ter, randomized, double-blind, active-controlled, parallel-
group, 24-month trial. In total, 1360 postmenopausal women
(mean age 72.1 years) with severe osteoporosis were
randomized following a 1:1 scheme to receive either subcuta-
neous teriparatide (20 μg daily) plus an oral weekly placebo or
oral risedronate (35 mg weekly) plus a subcutaneous daily
placebo for up to 24 months. Patients were enrolled at 116
centers in 14 countries across Europe, South America, and
North America.
Eligible participants were ambulatory postmenopausal
women aged > 45 years with a baseline bone mineral density
(BMD) T-score less than or equal to − 1.50 standard devia-
tions (SD) at the femoral neck, total hip, or lumbar spine.
Patients had to have radiographic evidence of at least two
moderate (between a 26% and 40% reduction in vertebral
body height) or one severe (more than 40% reduction in ver-
tebral body height) prevalent vertebral fragility fractures ac-
cording to the classification of Genant et al. [7]. Patients were
excluded if they had (a) low serum 25-hydroxy-vitamin D
levels (< 9.2 ng/mL or 23 nmol/L), (b) abnormally elevated
serum intact parathyroid hormone (PTH [1-84]) at baseline (>
72 pg/mL or > 7.6 pmol/L), or (c) significantly impaired renal
function as defined by a calculated endogenous creatinine
clearance of < 30 mL/min/m2. Prior use of bisphosphonates
or other osteoporosis drugs was allowed.
The primary study endpoint was the incidence of new ra-
diographic vertebral fractures (VFx). A new VFx was defined
as a vertebral body height loss of at least 20% (and 4 mm) of a
vertebra that was unfractured at baseline, based on a 6-point
placement of the vertebral bodies from T4 to L4, and con-
firmed by an increase by one or more severity grades accord-
ing to the semiquantitative grading (SQ) scale by Genant et al.
[7]. All VFx were centrally adjudicated by two radiologists
blinded to treatment (BioClinica, San Francisco, CA, USA).
Key secondary endpoints included the incidence of pooled
new and worsened VFx, clinical fractures (a composite of
clinical VFx and non-vertebral fragility fractures [NVFFx]),
NVFFx (excluding pathologic fractures and fractures of the
skull, face, fingers, metacarpals, and toes), and a subgroup of
major NVFFx involving the hip, radius, humerus, rib, pelvis,
tibia, and femur [1].
A clinical VFx was defined as an episode associated with
signs and symptoms highly suggestive of a VFx. These in-
clude severe back pain of acute onset; pain with little or no
exertion; pain localized to a specific vertebra and associated
with limited back mobility; pain relieved by bed rest; pain
worsened when upright, coughing, or sneezing; limited back
flexion; or paravertebral muscle tenderness secondary to
spasms, confirmed with the detection of a radiographic VFx
by the centralized X-ray imaging readers. Analyses of non-
vertebral and pooled clinical fractures were based on all ran-
domized patients who received at least one dose of the inves-
tigational product (full analysis set). Further study design,
entry criteria, and methodology details are described by
Kendler et al. [1] in their article summarizing the trial’s main
efficacy and safety results.
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Statistical analyses
The cumulative incidence of patients with at least one FRAX®-
defined MOF during the 24 months of follow-up was estimated
using Kaplan-Meier analyses. Treatment comparison was based
on the stratified log-rank test adjusted for the two stratification
factors used at randomization, i.e., the antecedent of a clinical
vertebral fracture in the 12months prior to study entry and recent
use of bisphosphonates [1]. Patients who were lost to follow-up,
died, or completed the studywithout experiencing a fracturewere
censored at the last date of contact.
The overall hazard ratio (HR) during the 24 months of
follow-up was calculated as part of the stratified log-rank test
calculations to estimate the treatment effect of teriparatide
versus risedronate. Additionally, an extended Cox regression
model was used to estimate the adjusted hazard ratios between
both treatment groups at different times of follow-up. This
model was adjusted by the following: treatment; antecedent
of recent clinical vertebral fractures; recent use of bisphospho-
nate; age (years); baseline BMD at the femoral neck (gm/
cm2); baseline 25-hydroxy-vitamin D concentration (ng/
mL); geographical region defined as North America (US and
Canada), South America (Argentina and Brazil), and Europe
(all other countries). This model included a time-varying co-
variate treatment-by-time interaction.
Incidence rates expressed as a number of events per 100 pa-
tients/years, and corresponding incidence rate ratios (IRRs) with
corresponding 95% confidence interval (CI) and p values were
also estimated at different 6-month intervals. The incidence rate
was calculated as the number of patients who experienced at least
one fracture event in the respective time interval divided by the
total amount of person-time contributed by the population at risk
during each 6-month time period. Patients who had a fracture in a
given period were not excluded from the analyses for incident
rate estimates in later periods. Each patient contributed time at
risk in each of the four time periods that were analyzed. These
analyses were conducted in the full analysis set that included all
randomized patients who received ≥ 1 dose of either investiga-
tional product. Analyses were performed under SAS 9.4.
Results
In total, 16 patients (cumulative incidence 2.6%) had one ormore
low trauma FRAX®-definedMOF in the teriparatide group com-
pared with 40 patients (cumulative incidence 6.4%) in the
risedronate group (overall HR 0.40; 95% CI 0.23–0.68; p =
0.001) (Fig. 1). The per-protocol analysis yielded similar results
with 14 (2.7%) and 36 (6.8%) of the patients treated with
teriparatide and risedronate sustaining a FRAX®-defined MOF,
respectively (HR 0.39; 95% CI 0.23–0.68; p = 0.002).
Fig. 1 Kaplan-Meier estimates of
the cumulative incidence of the
first FRAX®-defined major
osteoporotic fracture. *p value
from the stratified log-rank test
adjusted for antecedent of recent
clinical vertebral fractures and re-
cent bisphosphonate use
Table 1 Number of major osteoporotic fractures (FRAX®) by location
(full analysis population)
Teriparatide (N = 680) Risedronate (N = 680)
Clinical vertebral 7 24
Radius 6 10
Hip 2 5
Humerus 4 2
Total number of MOF 19 41
MOF, major osteoporotic fractures. Note: Ulna fractures not included
(teriparatide, n = 0; risedronate, n = 5)
Osteoporos Int
At 24 months, clinical vertebral fractures were the most
frequent fractures occurring in seven patients in the
teriparatide group (cumulative incidence 1.1%) compared
with 24 patients (cumulative incidence 3.9%) in the
risedronate group (overall HR 0.29; 95% CI 0.14–0.58; p =
0.002). Refer to Table 1 for individual FRAX®-defined MOF
locations.
The cumulative incidence for FRAX®-defined MOF,
based on Kaplan-Meier estimates, and the adjusted HRs, esti-
mated using the extended Cox model, is presented in Table 2.
After 7 months of treatment, the HR with respect to the oc-
currence of FRAX®-defined MOF became statistically signif-
icant in patients treated with teriparatide compared with pa-
tients treated with risedronate (HR at 7 months 0.50; 95% CI
0.26–0.93; p = 0.03). Similar results were observed for the
incidence of clinical fractures (i.e., clinical vertebral and
NVFFx) (Table 3).
The incidence rates of FRAX®-defined MOF and clinical
fractures by 6-month periods during 24 months of treatment are
presented in Figs. 2 and 3, respectively. The overall incidence
rate of FRAX®-definedMOF during the 24months of follow-up
(expressed as a number of fracture events per 100 patient-years)
was lower in the teriparatide group than in the risedronate group
(1.33 [95% CI 0.76–2.15] and 3.35 [95% CI 2.41–4.51], respec-
tively), with an estimated overall IRR of 0.40 (95% CI 0.22–
0.71; p = 0.002). Incidence rates of the clinical fractures, estimat-
ed overall and by 6-month periods, showed similar results, with a
lower incidence rate in the teriparatide group compared with the
risedronate group (2.52 [95% CI 1.71–3.55] and 5.18 [95% CI
4.00–6.57], respectively), with an estimated overall IRR of 0.49
(95% CI 0.31–0.75; p = 0.001). The largest reduction in the
fracture incidence rate in the teriparatide group, when compared
with the risedronate group, occurred at the 6- to 12-month period
for both types of fractures (Fig. 2).
Table 2 Cumulative incidence of
patients with ≥ 1 FRAX®-defined
major osteoporotic fracture and
adjusted hazard ratios estimated
with an extended Cox regression
model at different time points of
follow-up
Teriparatide (n = 680) Risedronate (n = 680) HR (95% CI) p value
At 3 months 4 (0.6%) 4 (0.6%) 0.62 (0.27, 1.41) 0.251
At 6 months 9 (1.4%) 12 (1.8%) 0.52 (0.27, 1.02) 0.057
At 7 months 9 (1.4%) 17 (2.6%) 0.50 (0.26, 0.93) 0.030
At 8 months 9 (1.4%) 18 (2.8%) 0.47 (0.26, 0.86) 0.015
At 9 months 9 (1.4%) 19 (3.0%) 0.45 (0.24, 0.81) 0.008
At 12 months 10 (1.5%) 24 (3.8%) 0.38 (0.20, 0.72) 0.003
At 15 months 12 (1.9%) 28 (4.4%) 0.32 (0.14, 0.71) 0.005
At 18 months 14 (2.2%) 33 (5.3%) 0.27 (0.10, 0.74) 0.011
At 21 months 15 (2.4%) 36 (5.8%) 0.23 (0.07, 0.79) 0.020
At 24 months 16 (2.6%) 40 (6.4%) 0.20 (0.05, 0.86) 0.031
BMD, bone mineral density; CI, confidence interval; HR, hazard ratio (teriparatide versus risedronate). Adjusted
by treatment, antecedent of recent clinical vertebral fracture, recent use of bisphosphonate, age, baseline femoral
neck BMD, baseline 25-hydroxy-vitamin D concentration, geographical region, and time-varying covariate
treatment-by-time interaction
Table 3 Cumulative incidence of
patients with ≥ 1 pooled clinical
fractures (clinical vertebral and
non-vertebral) and adjusted haz-
ard ratios estimated with an ex-
tended Cox regression model at
different time points of follow-up
Teriparatide (n = 680) Risedronate (n = 680) HR (95% CI) p value
At 3 months 6 (0.9%) 7 (1.0%) 0.70 (0.36, 1.37) 0.299
At 6 months 12 (1.8%) 17 (2.6%) 0.62 (0.37, 1.07) 0.085
At 7 months 12 (1.8%) 23 (3.6%) 0.60 (0.36, 0.99) 0.046
At 8 months 13 (2.0%) 25 (3.9%) 0.58 (0.36, 0.93) 0.024
At 9 months 14 (2.1%) 26 (4.0%) 0.56 (0.35, 0.88) 0.012
At 12 months 18 (2.8%) 34 (5.3%) 0.49 (0.31, 0.78) 0.003
At 15 months 22 (3.5%) 39 (6.1%) 0.44 (0.26, 0.76) 0.003
At 18 months 26 (4.1%) 49 (7.8%) 0.39 (0.20, 0.77) 0.007
At 21 months 27 (4.3%) 55 (8.8%) 0.35 (0.15, 0.81) 0.014
At 24 months 30 (4.8%) 61 (9.8%) 0.31 (0.11, 0.86) 0.024
BMD, bone mineral density; CI, confidence interval; HR, hazard ratio (teriparatide versus risedronate). Adjusted
by treatment, antecedent of recent clinical vertebral fracture, recent use of bisphosphonate, age, baseline femoral
neck BMD, baseline 25-hydroxy-vitamin D concentration, geographical region, and time-varying covariate
treatment-by-time interaction
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Discussion
In our analysis, patients treated with teriparatide had a 60% lower
risk of sustaining FRAX®-defined major osteoporotic fractures
during the 24-month treatment period, compared with those pa-
tients treated with risedronate. These results support and comple-
ment previous research indicating the increased antifracture effi-
cacy of teriparatide over risedronate, alendronate, and placebo in
postmenopausal women with severe osteoporosis and in
glucocorticoid-induced osteoporosis [1, 8–10].
Our findings show similar fracture reductions using
FRAX®-defined MOF compared with the predefined clinical
fractures, which includes clinical vertebral and a more extend-
ed list of non-vertebral fracture sites.
Several other investigators have reported efficacy results
using the FRAX®-defined MOF endpoint [3, 4, 11]. In the
Abaloparatide Comparator Trial in Vertebral Endpoints
(ACTIVE), Miller and colleagues [3] reported a 70% reduc-
tion in MOF in patients treated with abaloparatide compared
with those who received placebo. This Phase 3 trial also com-
pared abaloparatide with teriparatide for MOF, and at 18
months, the Kaplan-Meier-estimated event rate was 1.5% for
the abaloparatide group versus 3.1% for the teriparatide group
(HR 0.45; 95% CI 0.21–0.95; p = 0.03), with most of the
MOF in this comparison being wrist fractures [3]. Similarly,
in a large, multinational, randomized controlled trial involving
postmenopausal women randomized to receive either
romosozumab, an anti-sclerostin antibody, or alendronate
over 12 months, Saag et al. [4] reported FRAX®-defined
MOF event rates of 3.0% and 4.2%, respectively, with a sta-
tistically nonsignificant difference between the two drugs (HR
0.72; p = 0.053).
Early antifracture efficacy has been highlighted as a major
need in osteoporosis care, particularly for those patients with
recent fractures who are at imminent risk of fracture. In the
current analysis, there was a statistically significant reduction
in fractures between treatment groups as early as seven
months for both categories of clinical fractures analyzed, with
Fig. 2 Incidence rates of FRAX®-defined major osteoporotic fracture
(number of events per 100 patient-years) by 6-month periods and overall
(0 to 24 months). Note: the incidence rates during each of the four 6-
month period intervals are calculated as the number of patients who
experienced at least one fracture event in the respective 6-month period,
divided by the total amount of person-time contributed by the population
at risk during the respective time interval. The overall incidence rate is
estimated from 0 to 24 months
Fig. 3 Incidence rates of pooled
clinical fractures (clinical
vertebral and non-vertebral)
(number of events per 100 pa-
tient-years) by 6-month periods
and overall (0 to 24 months).
Note: data are presented as inci-
dence rate. The incidence rate is
calculated as the number of pa-
tients who experienced at least
one fracture event in the respec-
tive 6-month period, divided by
the total amount of person-time
contributed by the population at
risk during the respective time
interval.
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a statistically significant reduction in the IRR during the 6- to
12-month period.
These results add to the body of evidence suggesting a
more rapid and greater fracture risk reduction in patients treat-
ed with anabolic therapies compared with antiresorptives [1,
4, 12, 13]. Our data confirm previous findings from the pivotal
Phase 3 Fracture Prevention Trial, where a reduction in non-
vertebral fracture risk was suggested starting after eight
months of treatment with 20 or 40 μg of daily teriparatide
[9]. This progressively increased, reaching statistical signifi-
cance at the end of the study (i.e., at 20 months) in the Kaplan-
Meier analyses [9]. Further to this early response, in a post hoc
analysis of the Fracture Prevention Trial, Lindsay et al. [14]
reported that increasing duration of teriparatide treatment was
associated with reduced risk of NVFFx when compared with
placebo. In that analysis, the Cox model showed that the rel-
ative hazard of specified NVFFx decreased by 9.5% for each
additional month of teriparatide versus placebo (HR = 0.905;
95% CI 0.895–0.931, p = 0.002) [14]. Therefore, given its
greater antifracture efficacy, early and more rapid onset of
effect, teriparatide appears to be a superior clinical option to
oral bisphosphonates for patients at high and imminent risk of
fracture [15, 16]. No equivalent data comparing teriparatide
with other antiresorptives are currently available.
This early efficacy of teriparatide compared with
risedronate is also of clinical interest, as it has been suggested
previously, using results from the combination of the multi-
center Vertebral Efficacy with Risedronate Therapy (VERT)
trials, that risedronate reduces the risk of clinical vertebral
fractures in postmenopausal women with osteoporosis within
6 months of starting treatment (RR = 0.08; 95%CI 0.01–0.63)
[17]. Results of that analysis suggest a 69% reduction in risk at
one year (RR = 0.31; 95% CI 0.12–0.78) [17].
The current analysis has a number of strengths and limita-
tions. The VERO study was the first randomized controlled
trial that assessed fractures as the primary efficacy endpoint in
a large subgroup of patients pretreated with bisphosphonates,
thus reflecting real life, as in many countries worldwide,
teriparatide use is limited to patients who develop fracture
while receiving antiresorptive therapy. The VERO study pop-
ulation is based on patients with high fracture risk, a popula-
tion that should be considered for osteoanabolic therapy.
Furthermore, patient selection was based on strong predictors
of fracture risk, given the inclusion of a combination of mul-
tiple or severe prevalent vertebral fractures with low BMD,
which both are independent and additive indicators of high
imminent fracture risk [18]. The analysis of the FRAX®-de-
fined MOF endpoint was a post hoc analysis; however, the
extended Cox regression model to assess the speed of the
clinical fracture efficacy was predefined in the statistical anal-
ysis plan. Finally, given the patient population analyzed, these
results may not be generalized to men, premenopausal wom-
en, or patients with less severe osteoporosis.
In conclusion, our post hoc analysis of the VERO trial
shows that, in postmenopausal women with severe osteopo-
rosis, teriparatide treatment was more efficacious than
risedronate, with a 60% lower risk of FRAX®-defined MOF
occurrence during the 24-month treatment period. Our study
also detected a significant reduction of risk at seven months of
treatment, confirming that this osteoanabolic treatment is par-
ticularly indicated for patients at imminent risk of fractures.
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Osteoporos Int
Berghe, R. Witvrouw; Brazil: J. Borges, M. Castro, L.A. Russo,
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Pnevmaticos; Hungary: E. Kanakaridu, K. Kudlak, P. Lakatos,
K. Nagy, P. Somogyi, P. Suranyi, Z. Valkusz; Italy: G. Bianchi,
M.L. Brandi, S. Giannini, G. Isaia, S. Minisola, G. Osella, M.
Rossini; Poland: T. Blicharski, J. Brzezicki, P. Leszczynski, M.
Mazurek, M. Rell-Bakalarska, J. Supronik; Spain: M.J.
Amerigo, M. Bernad, E. Casado, N. Chozas, M. Díaz-Curiel, J.
Malouf-Serra, J.A. Román, F.J. Tarazona; USA and Puerto Rico:
N. Binkley, M. Bolognese, P. Bressler, M. Carroll, A. Chang, D.
Cox, A. de la Llana, A. Dulgeroff, H. El-Kadi, M. Goldberg, S.
Greenspan, H. Kenney, A. Kivitz, M.E. Lewiecki, M. Lillestol,
P. Miller, A. Myers, P. Norwood, M. Perini, S. Rao, R.R.
Recker, C.P. Recknor, H. Rodríguez, K.G. Saag, R. Sachson,
C. Shuhart, O. Soto-Raíces, M. Spiegel.
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